Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 310 followers
Latest posts
Last updated about 2 hours ago
4DMT’s stock climbs as eye disease gene therapy patients keep jettisoning injections
about 2 hours ago
4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing...
Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
about 17 hours ago
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise...
AbbVie’s IL-1 asset misses mark as monotherapy in phase 2 ulcerative colitis study
about 19 hours ago
AbbVie is ending development of an IL-1 asset as a monotherapy in...
Dexcom CEO Kevin Sayer to pass torch to COO Jake Leach
about 20 hours ago
After taking on the title of president earlier this year, Dexcom’s Jake...
AbbVie's rumored $1B pursuit of Gilgamesh could fit into its growing neuroscience portfolio
about 20 hours ago
On a day when AbbVie revealed booming sales of Skyrizi and Rinvoq...
Bristol Myers touts commercial execution, reckons with recent clinical setbacks
about 20 hours ago
Bristol Myers Squibb had a strong quarter, with key drugs old and...
Experts highlight how CRO-site partnerships advance phase III CV trials
about 22 hours ago
Fortrea and Flourish Research leaders discuss how strategic collaboration are improving outcomes...
Nuvectis axes ovarian cancer program after seeing phase 1b data
about 22 hours ago
Nuvectis Pharma has dropped plans to develop NXP800 in ovarian cancer after...
Vinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst
about 22 hours ago
The sudden departure of Vinay Prasad, M.D., from the FDA again threw...
Frazier Life Sciences raises $1.3B for latest early-stage biotech venture fund
about 23 hours ago
Frazier Life Sciences has gathered an impressive $1.3 billion in capital commitments...
AbbVie crowns Gilgamesh its next M&A target with $1B buyout talks: report
about 23 hours ago
AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. The Big...
NextCure antibody strengthens bones in mice with rare brittle bone disease
1 day ago
Maryland-based biotech NextCure is looking for partners to advance a candidate for...